Risk factors for hyperuricemia with HMG-CoA reductase inhibitors using a postmarketing surveillance database in Japan

Masayuki Hashiguchi, Jun Hakamata, Mikiko Shimizu, Junya Maruyama, Tsuyoshi Shiga, Mayumi Mochizuki

Research output: Contribution to journalArticle

Abstract

Background: Little is known about whether HMG-CoA reductase inhibitor(statin)treatment exerts an adverse effect on serum levels of uric acid. It remains unknown whether statin use is associated with an increased risk of hyperuricemia. The purpose of this study was to identify the risk factors for developing hyperuricemia or blood uric acid elevation associated with statin use utilizing the Japanese RAD-AR postmarketing surveillance database. Methods: We performed a nested case-control study using a postmarketing surveillance database in Japan. The database cohort included 26,914 cases of statin use in patients with hyperlipidemia. Participants received at least one type of statin, had a clear medication history of statin use, and no complication of hyperuricemia. Cases were defined as onset of hyperuricemia or blood uric acid elevation during statin intake. For each case, 20 controls were randomly selected and matched by time-point. The factors associated with an increased risk of hyperuricemia or blood uric acid elevation during statin intake examined included sex, age, body mass index, statin use duration, complications, concomitant medications, and clinical laboratory test values. Statin-associated hyperuricemia or blood uric acid elevation was identified based on abnormal elevation of blood uric acid concentrations beyond the reference range. Results: A total of 20,783 patients met the inclusion criteria, of whom 23 were in the case group. Two complicating factors, sympathetic inhibitory antihypertensive drugs (adjusted odds ratio[OR]: 4.22)and triglyceride level(adjusted OR: 2.48), were extracted for onset of hyperuricemia or blood uric acid elevation. Conclusion: This study suggested that the onset of hyperuricemia or blood uric acid elevation might increase with statin use in patients with complications of hypertriglyceridemia and concomitant administration of sympathetic inhibitory antihypertensive drugs.

Original languageEnglish
Pages (from-to)145-150
Number of pages6
JournalJapanese Journal of Clinical Pharmacology and Therapeutics
Volume49
Issue number4
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hyperuricemia
Japan
Databases
Uric Acid
Antihypertensive Agents
Hypertriglyceridemia
Hyperlipidemias
Case-Control Studies
Reference Values
Triglycerides
Body Mass Index

Keywords

  • HMG-CoA reductase inhibitor(statin)
  • Hyperuricemia
  • Nested case-control study
  • Postmarketing surveillance
  • Risk factor

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Risk factors for hyperuricemia with HMG-CoA reductase inhibitors using a postmarketing surveillance database in Japan. / Hashiguchi, Masayuki; Hakamata, Jun; Shimizu, Mikiko; Maruyama, Junya; Shiga, Tsuyoshi; Mochizuki, Mayumi.

In: Japanese Journal of Clinical Pharmacology and Therapeutics, Vol. 49, No. 4, 01.01.2018, p. 145-150.

Research output: Contribution to journalArticle

Hashiguchi, Masayuki ; Hakamata, Jun ; Shimizu, Mikiko ; Maruyama, Junya ; Shiga, Tsuyoshi ; Mochizuki, Mayumi. / Risk factors for hyperuricemia with HMG-CoA reductase inhibitors using a postmarketing surveillance database in Japan. In: Japanese Journal of Clinical Pharmacology and Therapeutics. 2018 ; Vol. 49, No. 4. pp. 145-150.
@article{b9cba1c0b44c462fb76e1f6c1ceb37db,
title = "Risk factors for hyperuricemia with HMG-CoA reductase inhibitors using a postmarketing surveillance database in Japan",
abstract = "Background: Little is known about whether HMG-CoA reductase inhibitor(statin)treatment exerts an adverse effect on serum levels of uric acid. It remains unknown whether statin use is associated with an increased risk of hyperuricemia. The purpose of this study was to identify the risk factors for developing hyperuricemia or blood uric acid elevation associated with statin use utilizing the Japanese RAD-AR postmarketing surveillance database. Methods: We performed a nested case-control study using a postmarketing surveillance database in Japan. The database cohort included 26,914 cases of statin use in patients with hyperlipidemia. Participants received at least one type of statin, had a clear medication history of statin use, and no complication of hyperuricemia. Cases were defined as onset of hyperuricemia or blood uric acid elevation during statin intake. For each case, 20 controls were randomly selected and matched by time-point. The factors associated with an increased risk of hyperuricemia or blood uric acid elevation during statin intake examined included sex, age, body mass index, statin use duration, complications, concomitant medications, and clinical laboratory test values. Statin-associated hyperuricemia or blood uric acid elevation was identified based on abnormal elevation of blood uric acid concentrations beyond the reference range. Results: A total of 20,783 patients met the inclusion criteria, of whom 23 were in the case group. Two complicating factors, sympathetic inhibitory antihypertensive drugs (adjusted odds ratio[OR]: 4.22)and triglyceride level(adjusted OR: 2.48), were extracted for onset of hyperuricemia or blood uric acid elevation. Conclusion: This study suggested that the onset of hyperuricemia or blood uric acid elevation might increase with statin use in patients with complications of hypertriglyceridemia and concomitant administration of sympathetic inhibitory antihypertensive drugs.",
keywords = "HMG-CoA reductase inhibitor(statin), Hyperuricemia, Nested case-control study, Postmarketing surveillance, Risk factor",
author = "Masayuki Hashiguchi and Jun Hakamata and Mikiko Shimizu and Junya Maruyama and Tsuyoshi Shiga and Mayumi Mochizuki",
year = "2018",
month = "1",
day = "1",
doi = "10.3999/jscpt.49.145",
language = "English",
volume = "49",
pages = "145--150",
journal = "Japanese Journal of Clinical Pharmacology and Therapeutics",
issn = "0388-1601",
publisher = "Japanese Society of Clinical Pharmacology and Therapeutics",
number = "4",

}

TY - JOUR

T1 - Risk factors for hyperuricemia with HMG-CoA reductase inhibitors using a postmarketing surveillance database in Japan

AU - Hashiguchi, Masayuki

AU - Hakamata, Jun

AU - Shimizu, Mikiko

AU - Maruyama, Junya

AU - Shiga, Tsuyoshi

AU - Mochizuki, Mayumi

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Little is known about whether HMG-CoA reductase inhibitor(statin)treatment exerts an adverse effect on serum levels of uric acid. It remains unknown whether statin use is associated with an increased risk of hyperuricemia. The purpose of this study was to identify the risk factors for developing hyperuricemia or blood uric acid elevation associated with statin use utilizing the Japanese RAD-AR postmarketing surveillance database. Methods: We performed a nested case-control study using a postmarketing surveillance database in Japan. The database cohort included 26,914 cases of statin use in patients with hyperlipidemia. Participants received at least one type of statin, had a clear medication history of statin use, and no complication of hyperuricemia. Cases were defined as onset of hyperuricemia or blood uric acid elevation during statin intake. For each case, 20 controls were randomly selected and matched by time-point. The factors associated with an increased risk of hyperuricemia or blood uric acid elevation during statin intake examined included sex, age, body mass index, statin use duration, complications, concomitant medications, and clinical laboratory test values. Statin-associated hyperuricemia or blood uric acid elevation was identified based on abnormal elevation of blood uric acid concentrations beyond the reference range. Results: A total of 20,783 patients met the inclusion criteria, of whom 23 were in the case group. Two complicating factors, sympathetic inhibitory antihypertensive drugs (adjusted odds ratio[OR]: 4.22)and triglyceride level(adjusted OR: 2.48), were extracted for onset of hyperuricemia or blood uric acid elevation. Conclusion: This study suggested that the onset of hyperuricemia or blood uric acid elevation might increase with statin use in patients with complications of hypertriglyceridemia and concomitant administration of sympathetic inhibitory antihypertensive drugs.

AB - Background: Little is known about whether HMG-CoA reductase inhibitor(statin)treatment exerts an adverse effect on serum levels of uric acid. It remains unknown whether statin use is associated with an increased risk of hyperuricemia. The purpose of this study was to identify the risk factors for developing hyperuricemia or blood uric acid elevation associated with statin use utilizing the Japanese RAD-AR postmarketing surveillance database. Methods: We performed a nested case-control study using a postmarketing surveillance database in Japan. The database cohort included 26,914 cases of statin use in patients with hyperlipidemia. Participants received at least one type of statin, had a clear medication history of statin use, and no complication of hyperuricemia. Cases were defined as onset of hyperuricemia or blood uric acid elevation during statin intake. For each case, 20 controls were randomly selected and matched by time-point. The factors associated with an increased risk of hyperuricemia or blood uric acid elevation during statin intake examined included sex, age, body mass index, statin use duration, complications, concomitant medications, and clinical laboratory test values. Statin-associated hyperuricemia or blood uric acid elevation was identified based on abnormal elevation of blood uric acid concentrations beyond the reference range. Results: A total of 20,783 patients met the inclusion criteria, of whom 23 were in the case group. Two complicating factors, sympathetic inhibitory antihypertensive drugs (adjusted odds ratio[OR]: 4.22)and triglyceride level(adjusted OR: 2.48), were extracted for onset of hyperuricemia or blood uric acid elevation. Conclusion: This study suggested that the onset of hyperuricemia or blood uric acid elevation might increase with statin use in patients with complications of hypertriglyceridemia and concomitant administration of sympathetic inhibitory antihypertensive drugs.

KW - HMG-CoA reductase inhibitor(statin)

KW - Hyperuricemia

KW - Nested case-control study

KW - Postmarketing surveillance

KW - Risk factor

UR - http://www.scopus.com/inward/record.url?scp=85052582005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052582005&partnerID=8YFLogxK

U2 - 10.3999/jscpt.49.145

DO - 10.3999/jscpt.49.145

M3 - Article

AN - SCOPUS:85052582005

VL - 49

SP - 145

EP - 150

JO - Japanese Journal of Clinical Pharmacology and Therapeutics

JF - Japanese Journal of Clinical Pharmacology and Therapeutics

SN - 0388-1601

IS - 4

ER -